Syndax Pharmaceuticals, Inc. $SNDX is Knott David M Jr’s 7th Largest Position

Knott David M Jr raised its holdings in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 21.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 428,000 shares of the company’s stock after acquiring an additional 75,222 shares during the period. Syndax Pharmaceuticals makes up about 2.7% of Knott David M Jr’s portfolio, making the stock its 7th biggest position. Knott David M Jr owned about 0.49% of Syndax Pharmaceuticals worth $6,585,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. AQR Capital Management LLC raised its holdings in shares of Syndax Pharmaceuticals by 478.8% during the first quarter. AQR Capital Management LLC now owns 377,444 shares of the company’s stock worth $4,637,000 after purchasing an additional 312,231 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Syndax Pharmaceuticals by 5.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,842 shares of the company’s stock valued at $705,000 after purchasing an additional 3,094 shares during the period. Caxton Associates LLP purchased a new stake in Syndax Pharmaceuticals in the first quarter valued at $257,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Syndax Pharmaceuticals by 18.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 200,696 shares of the company’s stock valued at $2,466,000 after purchasing an additional 30,596 shares during the last quarter. Finally, Teacher Retirement System of Texas grew its position in Syndax Pharmaceuticals by 11.9% during the 2nd quarter. Teacher Retirement System of Texas now owns 23,132 shares of the company’s stock worth $217,000 after purchasing an additional 2,458 shares during the period.

Syndax Pharmaceuticals Price Performance

NASDAQ:SNDX opened at $22.07 on Friday. The company has a quick ratio of 4.42, a current ratio of 4.40 and a debt-to-equity ratio of 5.32. Syndax Pharmaceuticals, Inc. has a 52 week low of $8.58 and a 52 week high of $22.73. The stock’s 50-day moving average price is $20.89 and its 200-day moving average price is $18.24. The stock has a market capitalization of $1.95 billion, a PE ratio of -6.71 and a beta of 0.42.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.78) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.14). The business had revenue of $68.73 million during the quarter, compared to analyst estimates of $64.75 million. Syndax Pharmaceuticals had a negative return on equity of 206.62% and a negative net margin of 165.37%.The business’s revenue for the quarter was up 792.6% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.10) EPS. As a group, equities analysts expect that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current fiscal year.

Analysts Set New Price Targets

SNDX has been the subject of a number of recent research reports. JPMorgan Chase & Co. reduced their price objective on Syndax Pharmaceuticals from $40.00 to $33.00 and set an “overweight” rating for the company in a research note on Wednesday, November 12th. Wall Street Zen lowered Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. BTIG Research reiterated a “buy” rating and set a $56.00 price target on shares of Syndax Pharmaceuticals in a research report on Tuesday, December 9th. Barclays boosted their price target on Syndax Pharmaceuticals from $22.00 to $35.00 and gave the company an “overweight” rating in a report on Monday, November 24th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Syndax Pharmaceuticals in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $37.90.

Insider Buying and Selling

In related news, CEO Michael A. Metzger sold 17,159 shares of Syndax Pharmaceuticals stock in a transaction on Monday, February 9th. The shares were sold at an average price of $21.03, for a total value of $360,853.77. Following the sale, the chief executive officer owned 491,690 shares of the company’s stock, valued at approximately $10,340,240.70. This trade represents a 3.37% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Keith A. Goldan sold 3,410 shares of Syndax Pharmaceuticals stock in a transaction on Monday, February 9th. The shares were sold at an average price of $21.03, for a total transaction of $71,712.30. Following the completion of the sale, the chief financial officer directly owned 140,429 shares in the company, valued at $2,953,221.87. This represents a 2.37% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 30,063 shares of company stock valued at $628,332 over the last 90 days. Company insiders own 4.10% of the company’s stock.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.